Want to see TRAW full AI Analyst Report?
TRAW Stock Chart & Stats
$0.49
-$0.03(-6.13%)
At close: 4:00 PM EDT
$0.49
-$0.03(-6.13%)
Day’s Range― - ―
52-Week Range$0.43 - $3.27
Previous CloseN/A
Volume182.49K
Average Volume (3M)206.36K
Market Cap
$8.15M
Enterprise Value$8.37
Total Cash (Recent Filing)$3.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Nov 12, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding15,368,277
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside104.08% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financing Access And RunwayThe private placement and ATM access provide funding visibility for ongoing antiviral development through early 2027. This supports execution of regulatory work and clinical preparation, although continued losses mean additional capital may eventually be required.
Influenza Pipeline ProgressA planned toxicology resubmission keeps the lead influenza program active despite earlier regulatory concerns. Advancing toward a human challenge study could generate meaningful clinical validation and improve the company’s development prospects.
Broad Antiviral PortfolioExpansion beyond influenza and COVID-19 gives Traws multiple potential applications in serious viral diseases. Collaborations with public-health agencies and plans for local manufacturing may strengthen development, access, and outbreak-response capabilities.
Bears Say
Persistent Losses And Cash BurnPersistent operating losses and negative cash generation indicate that the business cannot currently fund development internally. Reliance on equity financing increases dilution and leaves progress dependent on continued access to external capital.
Negative Shareholders' EquityNegative equity shows accumulated losses or write-downs have overwhelmed the capital base. Although the absence of debt reduces refinancing pressure, the weak balance sheet can constrain strategic flexibility and increase dependence on new funding.
Clinical And Regulatory Execution RiskRegulatory objections have delayed clinical advancement of the lead program and require additional toxicology and FDA responses. Prolonged review or further requirements could postpone proof-of-concept, extend cash burn, and weaken the development timeline.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.43 and its highest was $3.27 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $8.15M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Nov 12, 2026 which is in 79 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Aug 14, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.175.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.21.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,368,277 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went down -5.429%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc. (TRAW) is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for respiratory viral infections. The company’s activities center on research and development of drug candidates intended to treat or prevent illnesses such as influenza and COVID-19, with value creation primarily tied to advancing these candidates through clinical development and potential regulatory pathways.
TRAW Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.View all TRAW earnings summariesTRAW Stock 12 Month Forecast
Average Price Target
$1.00
▲(104.08% Upside)
Technical Analysis
Ownership Overview
12.38% Insiders
0.73% Mutual Funds
33.07% Other Institutional Investors
51.67% Public Companies and
Individual Investors